Bus company welcomes plan to tackle city traffic
A bus company has welcomed council plans to develop proposals to tackle Oxford's "devastating" traffic.
Oxford Bus Company previously urged Oxfordshire County Council to find a "Plan B", after the ongoing Botley Road closure delayed the authority's planned introduction of traffic filters.
The council responded to this by confirming it would be drafting new plans to deal with the city's congestion problem.
Luke Marion, the bus company's managing director, said he was "encouraged by the announcement" and "looked forward to engaging" with the council to "improve journeys" for bus users.
"A robust bus network is critical in order for the Council to achieve its sustainability targets on the county's roads which we are wholly supportive of," Mr Marion said.
"To further enhance the appeal of travelling by bus, we need journeys to be faster and more reliable than is currently possible.
"Present levels of congestion are having a devastating impact on our city which we're keen to help resolve through positive discussion."
Oxford Bus Company said journey times on the Abingdon Road had increased by an average of 17% since the Botley Road was closed, with services between Blackbird Leys and Oxford city centre slowing by 33% compared with 2013.
Following Mr Marion's correspondence, the council confirmed that potential options to improve travel conditions would be discussed by the cabinet.
The council had planned to introduce contentious traffic filters on several major roads in autumn 2024, but they were pushed back for another two years due to the ongoing closure of Botley Road.
Labour councillor Brad Baines previously argued argued that the county council plans did "not answer questions about affordability of bus services or routes going where people need to go".
"These are key barriers which are yet to be addressed or even considered."
You can follow BBC Oxfordshire on Facebook, X (Twitter), or Instagram.
Council urged for 'Plan B' to tackle congestion
LTNs and cycle lanes cost council almost £4m
City traffic filters postponed by Botley Road delay
Oxfordshire County Council
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
'Modest' house price increase for Stroud as other areas see declines
A NEW study has revealed that the Stroud district had the second-highest house price increase in Gloucestershire. Between December 2024 and April 2025, the area saw a 2.96 per cent rise in property values, according to an analysis by conveyancing specialists Brethertons. The study examined early 2025 house price trends to offer insights to potential buyers and sellers. The data showed that the average house price in the Stroud district rose from £337,088 in December 2024 to £347,059 in April 2025. Of all the locations in Gloucestershire, only Stroud and the Forest of Dean saw an increase in house prices. However, four areas in the county saw a decline in house prices including Cheltenham, Tewkesbury, Gloucester and Cotswolds. Steve Neasham, Business Development Partner at Brethertons, said: 'The largest fall was in the Cotswolds, where prices dropped by almost 6%, possibly reflecting a post-pandemic correction in one of the region's most in-demand rural areas. 'On the other hand, Forest of Dean recorded a 6.12% rise - the highest in the county - potentially driven by ongoing interest in more affordable countryside settings. 'Stroud also saw a modest increase of 2.96%, offering reassurance to homeowners in those areas.' Mr Neasham suggests that these declines may be linked to shifting buyer priorities or affordability pressures. The Cotswolds experienced the largest drop at just under six per cent, with house prices falling from £444,114 in December 2024 to £417,597 in April 2025. Gloucester, Tewkesbury, and Cheltenham also saw declines of 4.54 per cent, 4.15 per cent, and 1.74 per cent, respectively.
Yahoo
29 minutes ago
- Yahoo
City centre set for summer of new openings
WORCESTER is getting ready for a summer of new openings, with shops, cafes and restaurants all on the horizon. While the city centre is still reeling from the news that House of Fraser will be closing its store in Chapel Walk, there is still plenty to look forward to. Shop units in the city centre that have been empty for some time have now been snapped up by new businesses. READ MORE: Finishing touches on new Levantine restaurant which opens soon READ MORE: New steak and seafood restaurant gears up to open in city centre READ MORE: 'Wellness one-stop' cafe and yoga studio to open in city centre New signage is popping up in windows as they all gear up to open. Many of the new openings will be independent businesses. From a new steak and seafood restaurant to a shop selling replica lightsabers, there will be something new for everyone. Here are some of the new businesses arriving in the city centre soon: FOOD: Levantine restaurant Otto is getting ready to open in Cathedral Square (Image: Newsquest) Otto will soon be serving up Levantine dishes at its new restaurant on Cathedral Square. Managers recently said they are aiming to open in the week commencing June 30. Balance yoga studio and café will open soon (Image: Balance by Belle) Balance, a wellness business split across three levels, offering a yoga studio, therapy rooms for massages and facials and a café. The therapy rooms and yoga studio are already open, with the café to open soon. Nerdworks will soon open in St Martin's Quarter (Image: NQ) Nerdworks is aiming to open its St Martin's Quarter store in July, when they will offer PC gaming parts, replica lightsabers and Warhammer. MICROPUB: Weavers has opened on Foregate Street (Image: Newsquest) New micropub Weavers opened its doors on Foregate Street on June 20, replacing the Craft Inn. STEAK: Aegean Breeze will soon open in Chapel Walk (Image: NQ) Aegean Breeze is adding the finishing touches to their new steak and seafood restaurant in Chapel Walk. They are yet to confirm an opening date.
Yahoo
an hour ago
- Yahoo
Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select players during high profile matches at The Championships, Wimbledon in 2025. The world's oldest and most prestigious tennis tournament serves as a perfect backdrop to showcase Smith+Nephew's purpose of 'Life Unlimited' - making a difference in patients' lives through the excellence of a diverse Sports Medicine product portfolio and the application of new is a high-impact sport that places great stress on various areas of the body – especially joints – often resulting in injury. Some of the latest technologies and solutions from Smith+Nephew for joint repair include: REGENETEN◊ Bioinductive Implant: With more than 150,000 procedures1 completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact amongst those having surgery for rotator cuff tears; demonstrating lower re-tear rates than reported compared to conventional techniques.2-6 Backed by level one clinical evidence,2 the collagen-based implant supports the body's natural healing response to facilitate the formation of new tendon-like tissue to biologically augment the existing tendon and change the course of rotator cuff tear progression.7-12 CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant: Derived from a naturally occurring calcium carbonate known as aragonite, the CARTIHEAL Implant is a biphasic scaffold for cartilage repair and subchondral bone restoration.13-15 Shown to deliver clinically meaningful post-operative improvements in pain, function and quality of life,* the CARTIHEAL Implant is the only device approved for the treatment of knee cartilage and osteochondral defects in patients with or without mild to moderate osteoarthritis (KL 0-3).13,16 Q-FIX◊ KNOTLESS All-Suture Anchor: Building on the long-standing success and performance of the Q-FIX Family for best-in-class anchor fixation strength,**,17-21 the new Q-FIX KNOTLESS All-Suture Anchor raises the bar for all-suture anchor technology. With proprietary features and capabilities, the Q-FIX KNOTLESS All-Suture Anchor aims to set a new benchmark for soft tissue security†,22 and offer surgeons a new option for soft tissue-to-bone fixation indications across multiple joint spaces. 'Our inaugural turn sponsoring select players during The Championships, Wimbledon in 2024 was a tremendous success supporting athletes from across the globe - including Jasmine Paolini all the way to the Ladies Final,' said Christie van Geffen, SVP Global Sports Medicine Marketing for Smith+Nephew. 'We were able to uniquely feature the Smith+Nephew brand along with our leading Sports Medicine technology portfolio - designed to help weekend warriors and world-class athletes get back to competing and doing what they love.' If you would like to learn more about Smith+Nephew's leading Sports Medicine technology portfolio – including the CARTIHEAL AGILI-C Cartilage Repair Implant, the REGENETEN Bioinductive Implant and the Q-FIX KNOTLESS All-Suture Anchor - please visit here. - ends – Media Enquiries Dave Snyder +1 (978) 749-1440 Smith+Nephew *Over a 2 and 4 year follow up **As compared to competitive devices in fixation/pull-out benchtop testing †As compared to the competitive device in cyclic benchtop testing References Smith+Nephew. Internal Data. Ruiz Ibán MÁ, García Navlet M, Moros Marco S, et al. Augmentation of a Transosseous-Equivalent Repair in Posterosuperior Nonacute Rotator Cuff Tears With a Bioinductive Collagen Implant Decreases the Retear Rate at One Year: A Randomized Controlled Trial. Arthroscopy: The Journal of Arthroscopic & Related Surgery. 2023:1-14. Bushnell BD, Connor PM, Harris HW, et al. Retear rates and clinical outcomes at 1 year after repair of full-thickness rotator cuff tears augmented with a bioinductive collagen implant: a prospective multicenter study. JSES international. 2021;5(2):228. Hein J, Reilly JM, Chae J, Maerz T, Anderson K. Retear Rates After Arthroscopic Single-Row, Double Row, and Suture Bridge Rotator Cuff Repair at a Minimum of 1 Year of Imaging Follow-up: A Systematic Review. Arthroscopy. 2015;31(11):2274-2281. Camacho-Chacon JA, Cuenca-Espierrez J, Roda-Rojo V, et al. Bioinductive collagen implants facilitate tendon regeneration in rotator cuff tears. J Exp Orthop. 2022;9(1):53. Smith + Nephew overview of the outcomes associated with the standard of care for the surgical treatment of rotator cuff tears. Internal Report EO/SPM/REGENETEN/005/v1. Bokor DJ, Sonnabend D, Deady L, et al. Evidence of healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a collagen implant: a 2-year MRI follow-up. Muscles, Ligaments Tendons J. 2016;6(1):16-25. Schlegel TF, Abrams JS, Bushnell BD, Brock JL, Ho CP. Radiologic and clinical evaluation of a bioabsorbable collagen implant to treat partial-thickness tears: a prospective multicenter study. J Shoulder Elbow Surg. 2018 27(2):242-251. Van Kampen C, Arnoczky S, Parks P, et al. Tissue-engineered augmentation of a rotator cuff tendon using a reconstituted collagen scaffold: a histological evaluation in sheep. Muscles Ligaments Tendons J. 2013;3(3):229-235. Arnoczky SP, Bishai SK, Schofield B, et al. Histologic Evaluation of Biopsy Specimens Obtained After Rotator Cuff Repair Augmented With a Highly Porous Collagen Implant. Arthroscopy. 2017;33(2):278-283 Bokor DJ, Sonnabend DH, Deady L, et al. Healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a highly porous collagen implant: a 5-year clinical and MRI follow-up. Muscles, Ligaments Tendons J. 2019;9(3):338-347. McElvany MD, McGoldrick E, Gee AO, Neradilek MB, Matsen FA, 3rd. Rotator cuff repair: published evidence on factors associated with repair integrity and clinical outcome. Am J Sports Med. 2015;43(2):491-500. Altschuler N, Zaslav KR, Di Matteo B, et al. Aragonite-Based Scaffold Versus Microfracture and Debridement for the Treatment of Knee Chondral and Osteochondral Lesions: Results of a Multicenter Randomized Controlled Trial. Am J Sports Med. 2023;51(4):957-967. doi:10.1177/03635465231151252 Kon E, Di Matteo B, Verdonk P, et al. Aragonite-Based Scaffold for the Treatment of Joint Surface Lesions in Mild to Moderate Osteoarthritic Knees: Results of a 2-Year Multicenter Prospective Study. Am J Sports Med. 2021;49(3):588-598. Kon E, Filardo G, Shani J, et al. Osteochondral regeneration with a novel aragonite-hyaluronate biphasic scaffold: up to 12-month follow-up study in a goat model. J Orthop Surg Res. 2015;10:81. Conte P, Anzillotti G, Crawford DC, et al. Differential analysis of the impact of lesions' location on clinical and radiological outcomes after the implantation of a novel aragonite-based scaffold to treat knee cartilage defects. Int Orthop. 2024;48(12):3117-3126 Douglass NP, et al. Arthroscopy. 2017;33(5):977-985 e975. Ergun S, et al. Arthroscopy. 2020; 2(3):e263-e275. Smith+Nephew 2023. Internal Report. 10090792- Revision B. ArthroCare Corporation 2017. Internal Report. P/N 49190-03 Rev. B. Smith+Nephew 2024. Internal Report. 10144423 Rev B. Smith and Nephew 10144423 Rev B About Smith+Nephew Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise. For more information about Smith+Nephew, please visit and follow us on X, LinkedIn, Instagram or Facebook. Forward-looking Statements This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations. ◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
